Lin, Wei-Chou
Hsu, Fu-Shun
Kuo, Kuan-Lin
Liu, Shing-Hwa
Shun, Chia-Tung
Shi, Chung-Sheng
Chang, Hong-Chiang
Tsai, Yu-Chieh
Lin, Ming-Chieh
Wu, June-Tai
Kuo, Yu
Chow, Po-Ming
Liao, Shih-Ming
Yang, Shao-Ping
Hong, Jo-Yu
Huang, Kuo-How
Funding for this research was provided by:
Ministry of Science and Technology, Taiwan (104-2314-B-002-164-MY3, 103-2314-B-002-161-MY3)
National Taiwan University Hospital (103-S2349, 104-M2868, 105-S2978, 105-28)
Article History
Received: 30 April 2018
Revised: 29 August 2018
Accepted: 20 September 2018
First Online: 4 October 2018
Change Date: 11 February 2019
Change Type: Correction
Change Date: 11 February 2019
Change Type: Correction
Change Details: In Fig. 1b, upper part, the cell viability counts after treatment with cisplatin and TSA in T24 cells was by mistake a duplication of the image for NTUB1 on the left. In the corrected version of Fig. 1, the image was replaced appropriately.
Change Details: In Fig. 1b, upper part, the cell viability counts after treatment with cisplatin and TSA in T24 cells was by mistake a duplication of the image for NTUB1 on the left. In the corrected version of Fig. 1, the image was replaced appropriately.
Compliance with ethical standards
: The study that involve human participants and animal experiments have been approved by the institutional research ethics committee (no. 201112136RIC) and National Taiwan University College of Medicine and College of Public Health Institutional Animal Care and Use Committee (IACUC) (No. 20160117).
: The authors declare that they have no conflict of interest.